Jonathan A. Leff, MD

Jonathan joined Sofinnova Investments as an Executive Partner in
2020. With over 28 years of clinical development experience in the
biotechnology and pharmaceutical industry he focuses on providing
his strategic drug development expertise to aid companies from
target identification to the market.

Prior to joining Sofinnova, Jonathan most recently served as Senior
Vice President and Chief Medical Officer of Ascendis Pharma, a
biotechnology company developing medicines for rare endocrine
disorders. Previously Dr. Leff served as Executive Vice President,
Research and Development at InterMune (acquired by
Roche/Genentech in 2014) where he oversaw the development and
US approval of Esbriet® (oral pirfenidone) for the treatment of
idiopathic pulmonary fibrosis. Before InterMune, he was Chief
Medical Officer at KaloBios Pharmaceuticals, and Vice President and
Chief Medical Officer at Halozyme Therapeutics. Additionally, Dr. Leff
held various positions at Roche, Amgen, and Merck.
Jonathan earned a B.A. in Chemistry from the University of
Pennsylvania, and received his M.D. from the University of
Pennsylvania School of Medicine. He completed his medical training
in Internal Medicine, Pulmonary and Critical Care Medicine at
the University of Colorado, Denver. 

Jonathan A. Leff